Skip to main content
SpringerLink
Log in

Pulmonale Erkrankungen

  • Chapter
Neugeborenenintensivmedizin

  • 2936 Accesses

Zusammenfassung

Die Differenzierung zwischen Atemnotsyndrom (Surfactantmangel) und Ateminsuffizienz durch Immaturität kann schwierig sein (s. S. 76). Apnoeanfälle s. S. 360. Die meisten pulmonalen Erkrankungen des Neugeborenen gehen mit Atemnot einher:

  • Tachypnoe über 60/min (Aufrechterhaltung eines normalen Atemzeitvolumens trotz hohen Atemwegwiderstands)

  • sternale Einziehungen (vermehrte Retraktionskraft der Lunge durch erhöhte Oberflächenspannung bei noch weichem Thoraxskelett)

  • exspiratorisches Stöhnen (verbesserter Gasaustausch durch Hinauszögern des alveolären Kollapses)

  • Nasenflügeln (Einsatz der auxiliären Atemmuskulatur)

  • abgeschwächtes Atemgeräusch

  • blassgraues Hautkolorit

  • Zyanose (eher ein Zeichen für insuffiziente Behandlung!)

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Arias-Camison JM, Lau J, Cole CH, Frantz ID 3rd (1999) Meta-analysis of dexamethasone therapy started in the first 15 days of life for prevention of chronic lung disease in premature infants. Pediatr Pulmonol 28(3):167–74

    Article  PubMed  CAS  Google Scholar 

  2. Askie LM, Henderson-Smart DJ, Irwig L, Simpson JM (2003) Oxygen-saturation targets and outcomes in extremely preterm infants. N Engl J Med 349(10):959–67

    Article  PubMed  CAS  Google Scholar 

  3. Bancalari E, Claure N, Gonzalez A (2005) Patent ductus arteriosus and respiratory outcome in premature infants. Biol Neonate 88(3):192–201

    Article  PubMed  Google Scholar 

  4. Banks BA, Cnaan A, Morgan MA et al. (1999) Multiple courses of antenatal corticosteroids and outcome of premature neonates. North American Thyrotropin-Releasing Hormone Study Group. Am J Obstet Gynecol 181(3):709–17

    Article  PubMed  CAS  Google Scholar 

  5. Barrington KJ, Finer NN (2007) Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev (3):CD000509

    PubMed  Google Scholar 

  6. Baud O, Foix-L’Helias L, Kaminski M et al. (1999) Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med 341(16):1190–6

    Article  PubMed  CAS  Google Scholar 

  7. Baud O, Laudenbach V, Evrard P, Gressens P (2001) Neurotoxic effects of fluorinated glucocorticoid preparations on the developing mouse brain: role of preservatives. Pediatr Res 50(6):706–11

    Article  PubMed  CAS  Google Scholar 

  8. Bell EF, Acarregui MJ (2008) Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev (1):CD000503

    PubMed  Google Scholar 

  9. Bloom BT, Kattwinkel J, Hall RT et al. (1997) Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics 100(1):31–8

    Article  PubMed  CAS  Google Scholar 

  10. Brion LP, Soll RF (2008) Diuretics for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev (1):CD001454

    PubMed  Google Scholar 

  11. Brion LP, Primhak RA, Ambrosio-Perez I (2002) Diuretics acting on the distal renal tubule for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev (1):CD001817

    PubMed  Google Scholar 

  12. Brion LP, Primhak RA, Yong W (2006) Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. Cochrane Database Syst Rev (3):CD001694

    PubMed  CAS  Google Scholar 

  13. Carlo WA, Stark AR, Wright LL et al. (2002) Minimal ventilation to prevent bronchopulmonary dysplasia in extremely-low-birth-weight infants. J Pediatr 141(3):370–4

    Article  PubMed  Google Scholar 

  14. Chang HY, Hsu CH, Kao HA et al. (2003) Treatment of severe meconium aspiration syndrome with dilute surfactant lavage. J Formos Med Assoc 102(5):326–30

    PubMed  Google Scholar 

  15. Christensen RD, Hunter DD, Goodell H, Rothstein G (1992) Evaluation of the mechanism causing anemia in infants with bronchopulmonary dysplasia. J Pediatr 120(4 Pt 1):593–8

    PubMed  CAS  Google Scholar 

  16. Cole CH, Colton T, Shah BL et al. (1999) Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med 340(13):1005–10

    Article  PubMed  CAS  Google Scholar 

  17. Crochemore C, Lu J, Wu Y et al. (2005) Direct targeting of hippocampal neurons for apoptosis by glucocorticoids is reversible by mineralocorticoid receptor activation. Mol Psychiatry 10(8):790–8

    Article  PubMed  CAS  Google Scholar 

  18. Crowley P (2000) Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev (2):CD000065

    PubMed  Google Scholar 

  19. Darlow BA, Graham PJ (2007) Vitamin A supplementation to prevent mortality and short and long-term morbidity in very low birthweight infants. Cochrane Database Syst Rev (4):CD000501

    PubMed  Google Scholar 

  20. Durand M, Sardesai S, McEvoy C (1995) Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized, controlled trial. Pediatrics 95(4):584–90

    PubMed  CAS  Google Scholar 

  21. Eronen M, Pohjavuori M, Andersson S, Pesonen E, Raivio KO (1997) Prostacyclin treatment for persistent pulmonary hypertension of the newborn. Pediatr Cardiol 18(1):3–7

    Article  PubMed  CAS  Google Scholar 

  22. Fanaroff AA, Hack M (1999) Periventricular leukomalacia – prospects for prevention. N Engl J Med 341(16):1229–31

    Article  PubMed  CAS  Google Scholar 

  23. Finer NN, Carlo WA, Walsh MC et al. (2010) Early CPAP versus surfactant in extremely preterm infants. N Engl J Med 362(21):1970–9

    Article  PubMed  CAS  Google Scholar 

  24. Flenady VJ, Gray PH (2002) Chest physiotherapy for preventing morbidity in babies being extubated from mechanical ventilation. Cochrane Database Syst Rev (2):CD000283

    PubMed  Google Scholar 

  25. Fowlie PW, Davis PG, McGuire W (2010) Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev (7):CD000174

    PubMed  Google Scholar 

  26. Friedlich P, Noori S, Stein J et al. (2005) Predictability model of the need for extracorporeal membrane oxygenation in neonates with meconium aspiration syndrome treated with inhaled nitric oxide. J Pediatr Surg 40(7):1090–3

    Article  PubMed  Google Scholar 

  27. Gonzalez A, Sosenko IR, Chandar J, Hummler H, Claure N, Bancalari E (1996) Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. J Pediatr 128(4):470–8

    Article  PubMed  CAS  Google Scholar 

  28. Halliday HL (1996) Natural vs synthetic surfactants in neonatal respiratory distress syndrome. Drugs 51(2):226–37

    Article  PubMed  CAS  Google Scholar 

  29. Halliday HL, Ehrenkranz RA, Doyle LW (2003) Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev (1):CD001145

    PubMed  Google Scholar 

  30. Halliday HL, Ehrenkranz RA, Doyle LW (2009) Late (>7 days) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev (1):CD001145

    PubMed  Google Scholar 

  31. Halliday HL, Ehrenkranz RA, Doyle LW (2010) Early (<8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev (1):CD001146

    PubMed  Google Scholar 

  32. Halliday HL, Tarnow-Mordi WO, Corcoran JD, Patterson CC (1993) Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial). Arch Dis Child 69(3 Spec No):276–80

    Article  PubMed  CAS  Google Scholar 

  33. Izraeli S, Samra Z, Sirota L, Merlob P, Davidson S (1991) Genital mycoplasmas in preterm infants: prevalence and clinical significance. Eur J Pediatr 150(11):804–7

    Article  PubMed  CAS  Google Scholar 

  34. Jobe AH (2000) Which surfactant for treatment of respiratory-distress syndrome. Lancet 355(9213):1380–1

    Article  PubMed  CAS  Google Scholar 

  35. Jobe AH, Bancalari E (2001) Bronchopulmonary dysplasia. Am J Respir Crit Care Med 163(7):1723–9

    PubMed  CAS  Google Scholar 

  36. Kinsella JP, Truog WE, Walsh WF et al. (1997) Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn. J Pediatr 131(1 Pt 1):55–62

    PubMed  CAS  Google Scholar 

  37. Lam BC, Yeung CY (1999) Surfactant lavage for meconium aspiration syndrome: a pilot study. Pediatrics 103(5 Pt 1):1014–8

    Article  PubMed  CAS  Google Scholar 

  38. Lista G, Bianchi S, Castoldi F, Fontana P, Cavigioli F (2006) Bronchoalveolar lavage with diluted porcine surfactant in mechanically ventilated term infants with meconium aspiration syndrome. Clin Drug Investig 26(1):13–9

    Article  PubMed  CAS  Google Scholar 

  39. Liu CQ, Ma L, Tang LM et al. (2008) (A randomized controlled study on the efficacy of inhaled nitric oxide in treatment of neonates with meconium aspiration syndrome). Zhonghua Er Ke Za Zhi 46(3):224–8

    PubMed  Google Scholar 

  40. Lodygensky GA, Rademaker K, Zimine S et al. (2005) Structural and functional brain development after hydrocortisone treatment for neonatal chronic lung disease. Pediatrics 116(1):1–7

    Article  PubMed  Google Scholar 

  41. Mabanta CG, Pryhuber GS, Weinberg GA, Phelps DL (2003) Erythromycin for the prevention of chronic lung disease in intubated preterm infants at risk for, or colonized or infected with Ureaplasma urealyticum. Cochrane Database Syst Rev (4):CD003744

    PubMed  Google Scholar 

  42. Mehrabani D, Gowen CW Jr, Kopelman AE (1991) Association of pneumothorax and hypotension with intraventricular haemorrhage. Arch Dis Child 66(1 Spec No):48–51

    Article  PubMed  CAS  Google Scholar 

  43. Ng GY, Ohlsson A (2001) Cromolyn sodium for the prevention of chronic lung disease in preterm infants. Cochrane Database Syst Rev (2):CD003059

    PubMed  Google Scholar 

  44. Ng GY, da Siva O, Ohlsson A (2001) Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database Syst Rev (3):CD003214

    PubMed  Google Scholar 

  45. Ollikainen J, Hiekkaniemi H, Korppi M, Sarkkinen H, Heinonen K (1993) Ureaplasma urealyticum infection associated with acute respiratory insufficiency and death in premature infants. J Pediatr 122(5 Pt 1):756–60

    PubMed  CAS  Google Scholar 

  46. O‘Neil EA, Chwals WJ, O‘Shea MD, Turner CS (1992) Dexamethasone treatment during ventilator dependency: possible life threatening gastrointestinal complications. Arch Dis Child 67(1 Spec No):10–1

    Article  PubMed  Google Scholar 

  47. Patterson AM, Taciak V, Lovchik J, Fox RE, Campbell AB, Viscardi RM (1998) Ureaplasma urealyticum respiratory tract colonization is associated with an increase in interleukin 1-beta and tumor necrosis factor alpha relative to interleukin 6 in tracheal aspirates of preterm infants. Pediatr Infect Dis J 17(4):321–8

    Article  PubMed  CAS  Google Scholar 

  48. Poets CF, Sens B (1996) Changes in intubation rates and outcome of very low birth weight infants: a population-based study. Pediatrics 98(1):24–7

    PubMed  CAS  Google Scholar 

  49. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K (2004) A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus Beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol 21(3):109–19

    Article  PubMed  Google Scholar 

  50. Schelonka RL, Katz B, Waites KB, Benjamin DK Jr (2005) Critical appraisal of the role of Ureaplasma in the development of bronchopulmonary dysplasia with metaanalytic techniques. Pediatr Infect Dis J 24(12):1033–9

    Article  PubMed  Google Scholar 

  51. Seger N, Soll R (2009) Animal derived surfactant extract for treatment of respiratory distress syndrome. Cochrane Database Syst Rev (2):CD007836

    PubMed  Google Scholar 

  52. Shah P, Ohlsson A (2001) Alpha-1 proteinase inhibitor (a1PI) for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev (3):CD002775

    PubMed  Google Scholar 

  53. Shah SS, Ohlsson A, Halliday H, Shah VS (2007) Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants. Cochrane Database Syst Rev (4):CD002057

    PubMed  Google Scholar 

  54. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM (1988) Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 82(4):527–32

    PubMed  CAS  Google Scholar 

  55. Shinwell ES, Karplus M, Reich D et al. (2000) Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed 83(3):F177–81

    Article  PubMed  CAS  Google Scholar 

  56. Soll RF (2000) Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev (2):CD000144

    PubMed  Google Scholar 

  57. Soll RF, Blanco F (2001) Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev (2):CD000144

    PubMed  Google Scholar 

  58. Soll RF, Morley CJ (2001) Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev (2):CD000510

    PubMed  Google Scholar 

  59. Soll RF, Özek E (2009) Multiple versus single dose natural surfactant extract for severe neonatal respiratory distress syndrome. Cochrane Database Syst Rev (2):CD000141

    Google Scholar 

  60. Speer CP, Robertson B, Curstedt T et al. (1992) Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf. Pediatrics 89(1):13–20

    PubMed  CAS  Google Scholar 

  61. Stevens TP, Harrington EW, Blennow M, Soll RF (2007) Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for respiratory distress syndrome. Cochrane Database Syst Rev (4):CD003063

    PubMed  Google Scholar 

  62. STOP-ROP Multicenter Study Group (2000) Supplemental therapeutic oxygen for prethreshold retinopathy of prematurity (STOP-ROP), a randomized, controlled trial. I: Primary outcomes. Pediatrics 105(2):295–310

    Article  Google Scholar 

  63. Suresh GK, Davis JM, Soll RF (2001) Superoxide dismutase for preventing chronic lung disease in mechanically ventilated preterm infants. Cochrane Database Syst Rev (1):CD001968

    PubMed  Google Scholar 

  64. Thome UH, Ambalavanan N (2009) Permissive hypercapnia to decrease lung injury in ventilated preterm neonates. Semin Fetal Neonatal Med 14(1):21–7

    Article  PubMed  Google Scholar 

  65. Van Meurs KP, Wright LL, Ehrenkranz RA et al. (2005) Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med 353(1):13–22

    Article  PubMed  Google Scholar 

  66. Verder H, Albertsen P, Ebbesen F et al. (1999) Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks‘ gestation. Pediatrics 103(2):E24

    Article  PubMed  CAS  Google Scholar 

  67. Verder H, Bohlin K, Kamper J, Lindwall R, Jonsson B (2009) Nasal CPAP and surfactant for treatment of respiratory distress syndrome and prevention of bronchopulmonary dysplasia. Acta Paediatr 98(9):1400–8

    Article  PubMed  Google Scholar 

  68. Ward M, Sinn J (2003) Steroid therapy for meconium aspiration syndrome in newborn infants. Cochrane Database Syst Rev (4):CD003485

    PubMed  Google Scholar 

  69. Watts JL, Milner R, Zipursky A et al. (1991) Failure of supplementation with vitamin E to prevent bronchopulmonary dysplasia in infants less than 1,500 g birth weight. Eur Respir J 4(2):188–90

    PubMed  CAS  Google Scholar 

  70. Werner JC, Sicard RE, Hansen TW, Solomon E, Cowett RM, Oh W (1992) Hypertrophic cardiomyopathy associated with dexamethasone therapy for bronchopulmonary dysplasia. J Pediatr 120(2 Pt 1):286–91

    PubMed  CAS  Google Scholar 

  71. Wood B, Dubik M (1995) A new device for pleural drainage in newborn infants. Pediatrics 96(5 Pt 1):955–6

    PubMed  CAS  Google Scholar 

  72. Woodgate PG, Davies MW (2001) Permissive hypercapnia for the prevention of morbidity and mortality in mechanically ventilated newborn infants. Cochrane Database Syst Rev (2):CD002061

    PubMed  Google Scholar 

  73. Yeh TF, Lin YJ, Huang CC et al. (1998) Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics 101(5):E7

    Article  PubMed  CAS  Google Scholar 

  74. Yeh TF, Lin YJ, Lin HC et al. (2004) Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med 350(13):1304–13

    Article  PubMed  CAS  Google Scholar 

  75. Yoon BH, Romero R, Jun JK et al. (1997) Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia. Am J Obstet Gynecol 177(4):825–30

    Article  PubMed  CAS  Google Scholar 

  76. Yost CC, Soll RF (2000) Early versus delayed selective surfactant treatment for neonatal respiratory distress syndrome. Cochrane Database Syst Rev (2):CD001456

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Neonatologie, Charité Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin

    Prof. Dr. med. Michael Obladen (em. Direktor)

Authors
  1. Prof. Dr. med. Michael Obladen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Gießen und Marburg GmbH Standort Marburg, Baldinger Strasse, 35033, Marburg

    Rolf F. Maier (Direktor) (Direktor)

  2. Klinik für Neonatologie, Charité Virchow-Klinikum, Augustenburger Platz 1, 13353, Berlin

    Michael Obladen (em. Direktor) (em. Direktor)

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Obladen, M. (2011). Pulmonale Erkrankungen. In: Maier, R.F., Obladen, M. (eds) Neugeborenenintensivmedizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01069-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-01069-9_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-01068-2

  • Online ISBN: 978-3-642-01069-9

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation